Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.56 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 7/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426484 | 0.82 | PIM3 (0.51) | TRIM24TRIM33PIM3PIM1CYP2A6 | |
| SCHEMBL16067289 | 0.82 | TRIM24 (0.59) | TRIM24TRIM33PIM3PIM1CYP2A6 | |
| SCHEMBL29955189 | 0.81 | PIM3 (0.50) | TRIM24TRIM33PIM3PIM1CYP2A6 | |
| SCHEMBL672970 | 0.79 | TRIM24 (0.56) | TRIM24TRIM33PIM3PIM1CYP2A6 | |
| SCHEMBL671315 | 0.79 | TRIM24 (0.56) | TRIM24TRIM33PIM3PIM1CYP2A6 | |
| SCHEMBL29953212 | 0.79 | PIM3 (0.49) | TRIM24TRIM33PIM3PIM1CYP2A6 | |
| SCHEMBL29951284 | 0.79 | ERN1 (0.51) | TRIM24TRIM33PIM3PIM1CYP2A6 | |
| SCHEMBL1144808 | 0.77 | GSK3B (0.36) | TRIM24TRIM33MAPTCYP1A2CYP2C19 | |
| SCHEMBL9732966 | 0.77 | ALDH1A1 (0.56) | TRIM24TRIM33ALDH1A1MAPTCYP1A2 | |
| SCHEMBL3064496 | 0.74 | ERN1 (0.53) | TRIM24TRIM33PIM3PIM1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2968272-B1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-2968272-B1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| CN-1917921-A | Calcitonin gene related peptide receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | CN | disclosed |
| EP-1689493-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005065779-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | VDAC1, HTR3B, FAAH | TRIM24 3026/4885TRIM33 2201/4885PIM3 4648/4885 |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885 |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | CALCRL, CALCR, CALCA | TRIM24 4364/4885TRIM33 4602/4885PIM3 4594/4885 |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885 |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885 |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | TRIM24 1588/4885TRIM33 1937/4885PIM3 1444/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | TRIM24 3965/4885TRIM33 4561/4885PIM3 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.